- GALE-401 expected to initiate a Phase 3 clinical trial in Q2, 2017
- Top-Line results from NeuVax™ (nelipepimut-S) PRESENT Clinical Trial
- Webcast and conference call today at 2:00 p.m. P.T. / 5:00 p.m. E.T.
Here's a technical look at how to trade some of the most active stocks on the market right now.
The inevitable failure of Galena Biopharma's breast cancer vaccine NeuVax was apparent in shoddy clinical data presented four years ago. On Wednesday, the bear call on Galena was proven correct.
Galena (GALE) stock closed sharply higher on Wednesday after its breast cancer treatment received a Fast Track designation from the FDA.